Build vs. Buy Healthcare AI: A Decision Framework for Health System Leaders

The most expensive healthcare AI decision is not building instead of buying. It is choosing an architecture that cannot move beyond the first pilot. 

A health system builds a model for one service line. Another department buys a scribe. Revenue cycle adds a denial tool. Quality launches a separate surveillance project. Each initiative may work, but the organization accumulates disconnected data pipelines, governance processes, contracts, and work queues. 

The board sees an AI portfolio. The enterprise experiences AI fragmentation. 

The strategic decision is not simply build or buy. It is which capabilities should be owned, which should be purchased, and which shared intelligence layer should connect them.

The Three Real Options 

Option 1: Build internally 

The organization develops and operates the data pipelines, models, retrieval systems, user experiences, monitoring, and governance. 

This approach offers maximum design control and may be appropriate when the capability is strategically differentiating, the required data is unique, and the organization has durable engineering, clinical informatics, data science, security, and product capacity. 

The hidden challenge is not building the first model. It is maintaining integrations, retraining or updating components, monitoring performance, supporting users, documenting governance, responding to new regulations, and keeping the product relevant after the original team changes. 

Option 2: Buy point solutions 

The organization purchases products for specific tasks such as ambient documentation, coding, patient messaging, prior authorization, or referral management. 

Point solutions can deploy quickly and deliver focused value. The risk is cumulative complexity. Different products may read the same data, create overlapping alerts, use incompatible governance models, and require separate integrations and contracts. 

Option 3: Add an intelligence layer 

The organization keeps the EHR and core systems, connects the data required for defined use cases, grounds the intelligence in institutional knowledge, and deploys multiple clinical and operational workflows on a shared governed foundation. 

This option is not automatically better. It becomes attractive when several use cases depend on the same longitudinal patient context, evidence traceability, routing, and resolution process.

The Build-vs-Buy Scorecard  

Decision factor	Build internally	Buy point solution	Add intelligence layer
Speed to first use case	Slow to moderate	Fast	Moderate
Customization	Highest	Limited to product	High through configuration and grounding
Upfront cost	High	Lower per product	Moderate
Ongoing operating burden	Highest	Vendor-managed, but multiplied across products	Shared platform burden
Integration	Organization owns all	Often narrow	Designed across systems and use cases
Institutional knowledge	Fully controllable	Variable	Customer-controlled grounding
Governance	Organization must create	Product-specific	Shared governance framework
Scalability across use cases	Depends on platform discipline	Low to moderate	High if the shared context is reusable
Vendor dependency	Low external, high internal key-person risk	High	Moderate

The right answer may be hybrid. Build the elements that create strategic advantage, buy mature commodity capabilities, and use a shared intelligence layer to connect the workflows that depend on longitudinal context. 

The Hidden Cost Stack of Building Healthcare AI 

Internal proposals often focus on model development and underestimate the surrounding product. 

A production healthcare AI capability may require: 

• Data integration across FHIR, HL7, APIs, documents, claims, and legacy systems. 

• Patient identity resolution and terminology mapping. 

• Data quality monitoring and provenance. 

• Secure cloud or on-premise architecture, access controls, encryption, and audit logs. 

• Retrieval and institutional knowledge management. 

• Workflow design, role-based routing, escalation, and resolution tracking. 

• Model evaluation, monitoring, versioning, and rollback. 

• Human factors, clinician adoption, and change management. 

• Privacy, security, legal, compliance, and regulatory review. 

• Product support, incident response, and long-term ownership. 

  
  

NIST’s AI Risk Management Framework organizes responsible AI around governing, mapping, measuring, and managing risk. ONC’s HTI-1 rule adds transparency expectations for predictive decision support in certified health IT. FDA’s 2026 clinical decision support guidance further reinforces that intended use and the user’s ability to independently review the basis of a recommendation matter. 

These are not reasons to avoid AI. They are reasons to treat it as an enterprise capability rather than a model-development project. 

Five Questions That Clarify the Decision 

1. Is this capability strategically differentiating? 

If the workflow creates a unique competitive advantage and depends on proprietary data or operations, internal ownership may be justified. If it is a common task such as transcription, buying may be more rational. 

2. Does the use case require longitudinal, cross-system context? 

If the answer depends on notes, results, referrals, scheduling, authorization, and claims, a point solution may be too narrow and an intelligence layer may create more leverage. 

3. Can the organization support the capability for five years? 

Do not evaluate only the team needed to build the pilot. Evaluate the team needed to operate, monitor, improve, govern, secure, and support it after launch. 

4. How much institutional control is required? 

The organization may need control over protocols, thresholds, evidence, routing, data retention, and model-training terms. Clarify which controls are configurable, contractual, or unavailable. 

5. How quickly must value be proven? 

A two-year platform build may be strategically reasonable but commercially irrelevant if the organization needs to reduce denials or close referrals this year. 

The Case for Institution-Grounded Intelligence 

Healthcare workflows are not generic. Two health systems may use the same EHR but have different care pathways, escalation rules, documentation standards, and payer contracts. 

An effective enterprise platform should be configured around customer-approved institutional knowledge and improve through governed feedback from accepted findings, dismissed exceptions, audit outcomes, and denial history. 

The customer should control: 

• Enabled use cases. 

• Protocol and policy sources. 

• Thresholds and confidence requirements. 

• Role-based routing and escalation. 

• Retention and data-use terms. 

• Human review and approval. 

Customer data should remain protected in a customer-specific environment and should not be used to train shared models without explicit authorization.

A Better Way to Buy: Validate Before You Scale 

A healthcare AI procurement should begin with a narrow validation, not an enterprise-wide promise. 

Step 1: Define one exception 

Examples include an incomplete referral, unacknowledged result, documentation deficiency, authorization mismatch, or unsupported claim element. 

Step 2: Test on historical data 

Determine whether the required sources are available and whether the system can produce evidence-backed findings with acceptable precision. 

Step 3: Design the human workflow 

Identify who reviews, who can act, how the finding is dismissed or escalated, and what creates closure. 

Step 4: Measure impact 

Track accuracy, time saved, closure, prevented rework, financial impact, and user trust. 

Step 5: Expand only if the context is reusable 

The platform becomes strategic when the same integration, longitudinal timeline, institutional knowledge, and governance foundation support the next use case. 

Where Kana Fits 

Kana offers the intelligence-layer path. It is designed to connect existing clinical, operational, and financial systems, organize the longitudinal patient journey, apply customer-approved institutional knowledge, and route evidence-backed exceptions for human review. 

The intent is not to replace every point solution or prevent a health system from building internal capabilities. It is to provide a governed foundation for workflows that require shared context across systems and teams. 

The Bottom Line 

Build vs. buy is too small a question for enterprise healthcare AI. 

Build what differentiates you. Buy what is mature and commoditized. Create or adopt a shared intelligence layer for the workflows that depend on the same patient history, institutional rules, evidence, and resolution process. 

Frequently Asked Questions 

Question: When should a health system build AI internally? 

Answer: Build when the capability is strategically differentiating, the organization has unique data or workflows, and it can sustain engineering, product, clinical, security, governance, and support capacity over multiple years. 

Question: When is buying a healthcare AI product better? 

Answer: Buy when the task is mature, well-defined, and not strategically unique, and when a vendor can deploy faster with acceptable integration, governance, privacy, and commercial terms. 

Question: What is a healthcare intelligence layer? 

Answer: It is a governed platform that connects longitudinal clinical and operational data, applies institution-specific knowledge, surfaces evidence-backed exceptions, and routes them to human workflows across multiple use cases. 

Question: How should a health system evaluate AI vendor data use? 

Answer: Require explicit terms on data isolation, retention, access, subcontractors, model training, derived data, incident response, and deletion. Customer data should not train shared models without explicit authorization.

Before choosing build or buy, identify the shared layer. Kana can help determine whether the first use case should be built, bought, or deployed on a reusable intelligence foundation.